Kezar Raises $50M to Support Development of KZR-616 for Autoimmune Diseases
Crohn's Disease, News
Kezar Life Sciences raised $50 million in a financing round to support further clinical development of its lead drug candidate KZR-616 for the treatment of several autoimmune and inflammatory diseases, including ... Read more